Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Xenomics, Inc.
Xenomics Appoints Bruce A. Huebner as Chief Executive Officer and Board Member
October 23rd, 2009
Xenomics, Inc. (Pink Sheets:XNOM.PK)(FWB:XE7) a developer of trans-renal molecular diagnostic technologies, announced the appointment of Bruce A. Huebner, a veteran of the diagnostics industry, as Chief Executive Officer and board director. Concurrent with Mr. Huebner's appointment, Xenomics announced the formation of TrovaGene, Inc., a wholly owned subsidiary, under the laws of the State of Delaware, and plans to change the name of the company to "TrovaGene." The planned name change, by statutory merger, will be proposed to shareholders in the next 30 to 60 days. TrovaGene, under Mr. Huebner's guidance, will be engaged in refocusing the company's development and partnering programs. The...
Source: Medical Patent Business Week (2009-10-23)
|
